Eli Lilly's new weight-loss pill, sold under the name Foundayo, gives consumers a second option for a non-injectable GLP-1.

The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.

New drug Foundayo sets up battle with Novo Nordisk for oral obesity drugs